Theravance Biopharma, Inc.

As of June 30, 2026, Theravance Biopharma Inc carries a market capitalization of 773.17M, placing it among publicly traded companies globally. Its enterprise value stands at 467.62M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Theravance Biopharma Inc's next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Theravance Biopharma Inc has 51.89M shares outstanding.

As of June 30, 2026, Theravance Biopharma Inc trades at a trailing price-to-earnings ratio of 16.16. The price-to-sales ratio is 8.34, and the price-to-book ratio stands at 3.05.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.12 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Theravance Biopharma Inc trades at an EV/FCF ratio of 9.75, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 467.62M versus a market cap of 773.17M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Theravance Biopharma Inc maintains a current ratio of 13.54, meaning it holds 13.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.31, indicating elevated leverage, while an interest coverage ratio of -1.76 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Theravance Biopharma Inc posted a return on equity (ROE) of 20.91, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -1.23, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 12.01, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 18.30, useful for judging operating efficiency across full business cycles. The company generates approximately 995,132.62 in revenue per employee across its workforce of 91.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Theravance Biopharma Inc recorded 4.47M in income tax expense. That works out to an effective tax rate of 8.67, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 51.57M, leaving 47.10M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 23, 2026, Theravance Biopharma Inc's stock has gained approximately 25.21% over the past 52 weeks. The 50-day moving average sits at 14.73, while the 200-day moving average is 14.77.

Over the twelve months ended June 30, 2026, Theravance Biopharma Inc generated 91.30M in revenue and converted that into 47.10M in net income, yielding earnings per share of 0.91. EBITDA reached -1.78M, while operating income came in at 8.36M.

As of June 30, 2026, Theravance Biopharma Inc holds 339.32M in cash and equivalents against 33.76M in total debt, resulting in a net debt position of -192.36M. Total book value stands at 253.58M, with working capital of 337.77M providing operational flexibility.

Theravance Biopharma Inc produced 47.04M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7,002.40 in capital expenditures, free cash flow totaled 47.03M - equivalent to 0.92 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of 9.15 and net profit margin of 51.58 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 6.07, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.95, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Theravance Biopharma Inc shareholders.

As of June 30, 2026, Theravance Biopharma Inc has an Altman Z-Score of 1.62, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.